Terms: = Uterine cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
226 results:
1. FOXO3a deregulation in uterine smooth muscle tumors.
de Almeida TG; Ricci AR; Dos Anjos LG; Soares Junior JM; Maciel GAR; Baracat EC; Carvalho KC
Clinics (Sao Paulo); 2024; 79():100350. PubMed ID: 38636197
[TBL] [Abstract] [Full Text] [Related]
2. A phase 2 trial of zanidatamab in her2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Lumish M; Chui MH; Zhou Q; Iasonos A; Sarasohn D; Cohen S; Friedman C; Grisham R; Konner J; Kyi C; Rubinstein M; Troso-Sandoval T; Aghajanian C; Makker V
Gynecol Oncol; 2024 Mar; 182():75-81. PubMed ID: 38262242
[TBL] [Abstract] [Full Text] [Related]
3. Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology consensus statement.
Kim JH; Kim DY; Kim J; Noh JJ; Hwang WY; Baek MH; Choi MC; Joo WD; Lee YJ; Suh DH; Kim YB
J Gynecol Oncol; 2024 Mar; 35(2):e45. PubMed ID: 38216137
[TBL] [Abstract] [Full Text] [Related]
4. Whether specific genetic feature predicted immunotherapy efficacy: A case report.
Chen J; Pang L; He L; Li T; Cheng X
Medicine (Baltimore); 2024 Jan; 103(2):e36922. PubMed ID: 38215117
[TBL] [Abstract] [Full Text] [Related]
5. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
6. Targeting her2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Friedman CF; D'Souza A; Bello Roufai D; Tinker AV; de Miguel M; Gambardella V; Goldman J; Loi S; Melisko ME; Oaknin A; Spanggaard I; Shapiro GI; ElNaggar AC; Panni S; Ravichandran V; Frazier AL; DiPrimeo D; Eli LD; Solit DB
Gynecol Oncol; 2024 Feb; 181():162-169. PubMed ID: 38211393
[TBL] [Abstract] [Full Text] [Related]
7. Antibody-Drug Conjugates in Gynecologic cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract] [Full Text] [Related]
8. Decreased her2 expression in endometrial cancer following anti-her2 therapy.
Chui MH; Brown DN; Da Cruz Paula A; da Silva EM; Momeni-Boroujeni A; Reis-Filho JS; Zhang Y; Makker V; Ellenson LH; Weigelt B
J Pathol; 2024 Feb; 262(2):129-136. PubMed ID: 38013631
[TBL] [Abstract] [Full Text] [Related]
9. Mechanism of gemcitabine combined with lobaplatin in interventional treatment of locally advanced cervical cancer.
Lin Y; Yang Q
Anticancer Drugs; 2024 Feb; 35(2):209-217. PubMed ID: 37948339
[TBL] [Abstract] [Full Text] [Related]
10. The value of multiparametric MRI combined with clinical prognostic parameters in predicting the 5-year survival of stage IIIC1 cervical squamous cell carcinoma.
Qin F; Pang H; Ma J; Xu H; Yu T; Luo Y; Dong Y
Eur J Radiol; 2023 Dec; 169():111181. PubMed ID: 37939604
[TBL] [Abstract] [Full Text] [Related]
11. Single-nucleus RNA sequencing reveals heterogenous microenvironments and specific drug response between cervical squamous cell carcinoma and adenocarcinoma.
Lin S; Sun Y; Cao C; Zhu Z; Xu Y; Liu B; Hu B; Peng T; Zhi W; Xu M; Ding W; Ren F; Ma D; Li G; Wu P
EBioMedicine; 2023 Nov; 97():104846. PubMed ID: 37879219
[TBL] [Abstract] [Full Text] [Related]
12. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
[TBL] [Abstract] [Full Text] [Related]
13. The role of sialylation in gynecologic cancers.
Yang ST; Liu CH; Chao WT; Liu HH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2023 Sep; 62(5):651-654. PubMed ID: 37678990
[TBL] [Abstract] [Full Text] [Related]
14. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in uterine Serous Carcinoma.
Mutlu L; Manavella DD; Bellone S; McNamara B; Harold JA; Mauricio D; Siegel ER; Buza N; Hui P; Hartwich TMP; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner ES; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
Mol Cancer Ther; 2023 Dec; 22(12):1404-1412. PubMed ID: 37676984
[TBL] [Abstract] [Full Text] [Related]
15. Assessing the Genomic Landscape of Cervical cancers: Clinical Opportunities and Therapeutic Targets.
Friedman CF; Ravichandran V; Miller K; Vanderbilt C; Zhou Q; Iasonos A; Vivek M; Mishra P; Leitao MM; Broach V; Sonoda Y; Kyi C; Zamarin D; O'Cearbhaill RE; Konner J; Berger MF; Weigelt B; Momeni Boroujeni A; Park KJ; Aghajanian C; Solit DB; Donoghue MTA
Clin Cancer Res; 2023 Nov; 29(22):4660-4668. PubMed ID: 37643132
[TBL] [Abstract] [Full Text] [Related]
16. her2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial cancer.
Shen S; Ma W; Brown D; Da Cruz Paula A; Zhou Q; Iaosonos A; Tessier-Cloutier B; Ross DS; Troso-Sandoval T; Reis-Filho JS; Abu-Rustum N; Zhang Y; Ellenson LH; Weigelt B; Makker V; Chui MH
Mod Pathol; 2023 Nov; 36(11):100299. PubMed ID: 37558129
[TBL] [Abstract] [Full Text] [Related]
17. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract] [Full Text] [Related]
18. Epidemiology of cervical cancer in elderly women: Analysis of incidence, treatment, and survival using German registry data.
Neumeyer S; Tanaka LF; Liang LA; Klug SJ
Cancer Med; 2023 Aug; 12(16):17284-17295. PubMed ID: 37403686
[TBL] [Abstract] [Full Text] [Related]
19. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
Li J; Xue X; Zhang Y; Ding F; Wu W; Liu C; Xu Y; Chen H; Ou Q; Shao Y; Li X; Wu F; Wu X
Gynecol Oncol; 2023 Aug; 175():133-141. PubMed ID: 37356314
[TBL] [Abstract] [Full Text] [Related]
20. Clinically Aggressive uterine Epithelioid Leiomyosarcoma with Rhabdomyoblastic Differentiation and High Proliferation Rate: A Case Report.
Kim JY; Kim B
Am J Case Rep; 2023 May; 24():e939349. PubMed ID: 37190674
[TBL] [Abstract] [Full Text] [Related]
[Next]
